Clincosm LogoSign in Get a demo

SEFFIDiFA: Effectiveness of the Autologous Adipose Tissue Harvested With SEFFICARE Method for Treatment of DFU Minor Amputation

Sponsor
Azienda Ospedaliero-Universitaria di Modena (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05072353
Collaborator
University of Modena and Reggio Emilia (Other)
40
Enrollment
1
Location
1
Arm
34
Anticipated Duration (Months)
1.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Diabetic foot ulcers (DFU) are one of the complications of diabetes mellitus resulting from multiple causes such as neuropathy, ischemia, and infection that contribute to morbidity and amputation. The prevalence of DFU has been estimated to be 3 to 5 times higher than the overall population. Minor amputations (digital or transmetatarsal) are the treatment of choice in case of irreversible DFU. However, many minor amputations do not heal and require re-amputation. Improvements of healing rate after adipose stem cells (ASCs) injection through micro-fragmented autologous adipose tissue of the amputation stump following minor DFU amputation were demonstrated. The use of ASCs obtained from the superficial enhanced fluid fat injection technique (SEFFICARE) to improve the healing process after DFUs minor amputation is the object of the present study.

A single-center non-randomized prospective observational study will be performed.

The recruited patients will undergo local injection of superficial enhanced fluid fat after a lower limb minor amputation. Laboratory analysis to evaluate the composition of the tissue and stromal cell components harvested from adipose tissue with SEFFICARE system by using digital droplets PCR. These data will serve for making associations between the clinical outcome and characteristics of the cell population administered to each patient.

Condition or Disease Intervention/Treatment Phase
  • Device: SEFFICARE
 N/A

Detailed Description

Diabetic foot ulcers (DFU) are one of the complications of diabetes mellitus resulting from multiple causes such as neuropathy, ischemia, and infection that contribute to morbidity and amputation. The prevalence of DFU has been estimated to be 3 to 5 times higher than the overall population. Minor amputations (digital or transmetatarsal) are the treatment of choice in case of irreversible DFU. However, many minor amputations do not heal and require re-amputation. Improvements of healing rate after adipose stem cells (ASCs) injection through micro-fragmented autologous adipose tissue of the amputation stump following minor DFU amputation were demonstrated. The use of ASCs obtained from the superficial enhanced fluid fat injection technique (SEFFICARE) to improve the healing process after DFUs minor amputation is the object of the present study.

STUDY DESIGN: Single-center non-randomized prospective observational cohort study.

TREATMENT: Local injection of superficial enhanced fluid fat after a lower limb minor amputation. Laboratory analysis to evaluate the composition of the tissue and stromal cell components harvested from adipose tissue with SEFFICARE system by using digital droplets PCR. These data will serve for making associations between the clinical outcome and characteristics of the cell population administered to each patient.

INCLUSION CRITERIA:

  • type-1 and type-2 diabetes mellitus

  • age >18-years

  • both sexes

  • chronic diabetic distal ulcers/gangrene (digital or forefoot) intended as W-grade 1 to 3 according to WifI classification;

  • absence of active vascular issues or patients undergoing lower extremity revascularization to improve peripheral perfusion intended as I-grade 0 to 2 according to WIfi classification;

  • absence of infection signs or presence of soft tissue infection intended as fI-grade 0 to 2 according to Wifi classification, without radiologic signs of bone infection (negative X-ray for osteolytic lesions); SAMPLE SIZE: The correct sample size was calculated considering as primary endpoint the proportion of the healing stump. The sample size was calculated with the Score Z test comparing one proportion based on literature results to a reference value. Using a significance level of 0.05, power of 0.8, setting the H0 proportion of 0.80 and the Ha of 0.6 respectively, the result was 36 subjects. An additional 10% of subjects was considered taking into account eventual drop-out during the study. The final sample size inflated to 40 patients.

ENDPOINTS: Primary endpoint: percentage of stump healing; Secondary endpoints:

  • mean time for complete healing;

  • evaluation of risk factors afflicting healing/failure;

  • evaluation of reintervention (time elapsed since index operation, type, and indication);

  • the prevalence of peripheral diabetic polyneuropathy at baseline;

  • the percentage change in the pain score of NRS;

  • health-related quality of life evaluation, intended as changing of the SF-36 score;

  • collection of eventual adverse events related to the treatment procedure and eventual posthoc analysis.

  • evaluation of the adipose harvested tissue composition and stromal cell components STATISTICAL ANALYSIS: The categorical endpoints, i.e., the difference in the healing rate will be assessed with the chi-square test or Fisher's exact test. The continuous variables will be calculated by Kaplan-Meier curves and log-rank test. A univariate and multivariate logistic regression analysis will be applied to identify influencing factors on the categorical endpoints. To test the influence of multiple variables on continuous data, one/two-way ANOVA will be performed with Bonferroni's post-test.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Prospective cohort studyProspective cohort study
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection (SEFFICARE) Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation (SEFFIDiFA): Proposal of Basic Research and Prospective Observational Study
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.

Device: SEFFICARE
The SEFFI is a 5-step technique: Preparation: the lower/lateral abdomen is chosen as the donor site. Anesthesia: the donor site is injected with a local anesthetic. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom). Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained. The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound.

Outcome Measures

Primary Outcome Measures

  1. Healing [6 months]

    Healing was defined as complete re-epithelialization of the stump after suture removal without signs of cutaneous suffering, inflammation, infection, local swelling as determined by one investigator.

Secondary Outcome Measures

  1. healing time change [1, 2, 3, 4, 5, 6 months]

    mean time for complete healing

  2. risk factors afflicting healing/failure [0 month]

    evaluation of risk factors afflicting healing/failure

  3. reintervention [6 months]

    time elapsed since index operation, type, and indication

  4. diabetic peripheral neuropathy [0 month]

    the prevalence of DPN (probable) at baseline

  5. health-related quality of life change [1, 2, 3, 4, 5, 6 months]

    health-related quality of life evaluation, intended as changing of the SF-36 score

  6. adverse events related to the treatment procedure [6 months]

    collection of eventual adverse events related to the treatment procedure

  7. amount of adipose stem cells used for grafting [1 month]

    amount of adipose stem cells used for grafting

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • type-1 and type-2 diabetes mellitus

  • age >18-years

  • both sexes

  • chronic diabetic distal ulcers/gangrene (digital or forefoot) intended as W-grade 1 to 3 according to WifI classification;

  • absence of active vascular issues or patients undergoing lower extremity revascularization to improve peripheral perfusion intended as I-grade 0 to 2 according to WIfi classification;

  • absence of infection signs or presence of soft tissue infection intended as fI-grade 0 to 2 according to Wifi classification, without radiologic signs of bone infection (negative X-ray for osteolytic lesions);

Exclusion Criteria:

  • extensive ulcers with deep involving proximal forefoot and/or deep, full-thickness heel ulcer, with calcaneal involvement (W-grade 3 according to WifI classification);

  • active vascular issues [I-grade 3 according to Wifi classification];

  • ulcers with signs of moderate and/or severe infection (osteomyelitis and/or sepsis) [fI-grade 3 according to WifI classification];

  • severe comorbidities such as severe heart failure, liver failure, and/or psychiatric disorder;

  • previous oncological treatments (past 5 years) or ongoing and/or neoplastic lesions;

  • corticosteroid therapy;

  • coagulopathy;

  • infection of the harvesting site;

  • local anesthetic allergy;

  • immunosuppressive therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Civile di Baggiovara (Modena), Azienda Ospedaliero-Universitaria di Modena, Università di Modena e Reggio Emilia Modena Emilia-Romagna Italy 41126

Sponsors and Collaborators

  • Azienda Ospedaliero-Universitaria di Modena
  • University of Modena and Reggio Emilia

Investigators

  • Principal Investigator: Roberto Silingardi, MD, University of Modena and Reggio Emilia
  • Principal Investigator: Manuela Simoni, MD, PhD, University of Modena and Reggio Emilia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nicola Leone, MD, Azienda Ospedaliero-Universitaria di Modena
ClinicalTrials.gov Identifier:
NCT05072353
Other Study ID Numbers:
  • SEFFIDiFA_vers1.0
First Posted:
Oct 8, 2021
Last Update Posted:
Oct 8, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer

Study Results

No Results Posted as of Oct 8, 2021